Core Insights - Teva Pharmaceutical Industries Ltd. has launched Teva Rise, a global open innovation platform aimed at leveraging disruptive technologies such as AI and digital health to address challenges in the pharmaceutical industry and enhance patient outcomes [1][2][4] Company Initiatives - Teva Rise is designed to connect startups and technology companies with Teva's business units, facilitating the co-creation of solutions to real-world challenges in R&D, manufacturing, and commercial sectors [1][3][6] - The initiative is part of Teva's "Pivot to Growth" strategy, which focuses on transforming the company into a leading biopharmaceutical entity by adopting next-generation technologies [2][4][9] Investment and Collaboration - Teva plans to invest tens of millions of dollars in innovative solutions over the coming years to gain a competitive edge [3][4] - The platform will allow selected startups to pilot their solutions within Teva's global operations, thereby scaling their impact [3][9] Challenges Addressed - Teva Rise will focus on seven specific challenges, including human-predictive platforms for testing biologics, AI-powered clinical trial simulations, and optimizing patient experience with long-acting injectables [10] - Each challenge will be sponsored by a senior business leader at Teva, ensuring alignment with the company's strategic priorities [3][10] Industry Context - The launch of Teva Rise is timely as the pharmaceutical industry undergoes significant transformation driven by AI and digital technologies, which are reshaping drug development and patient care [2][4] - By fostering global partnerships with startups and tech innovators, Teva aims to enhance its operational capabilities and deliver meaningful value to patients worldwide [4][6]

Business Overview - AGC Group's business spans over 30 countries and regions [8] - In FY2024, AGC Group reported net sales of ¥2,067.6 billion and operating income of ¥125.8 billion, with approximately 53,700 employees [9] - Regional net sales: Japan & Asia ¥1,318.1 billion, Europe & Americas ¥492.6 billion, Americas operating income: ¥8.9 billion, Europe & Americas operating income: -¥13.8 billion [9] Value Creation Model - AGC aims for an ROE of 10% or higher through the creation of social value [18, 35] - The company has identified 10 key risks and opportunities as long-term social issues (materiality) [23] - AGC focuses on three social values: Blue planet (sustainable global environment), Innovation (innovative future society), and Well-being (safe and secure living) [18, 29, 30] Intellectual Capital & R&D - AGC's core technology is cultivated over more than 115 years [44] - The company has selected "Seven Key Technology Fields" and 21 corresponding "Focus Areas" through the Business and Technology Outlook (BTOL) initiative [53, 54] - AGC is investing more than ¥80 billion from 2024 to 2026 to address climate change [140] Human Capital - AGC is promoting human capital management through "AGC People: Driving our Growth!" to realize its purpose and achieve sustainable growth [107, 108] - The company aims to cultivate "dual-skilled talent" who combine business knowledge with digital skills to enhance competitiveness through accelerated DX [126, 127] - 30% of members in the Technology Division hold a Ph D [125] Sustainability - AGC aims for net-zero carbon emissions by 2050, with a 50% reduction in GHG emissions by 2030 compared to 2019 [137] - In 2024, Scope 1 and Scope 2 GHG emissions decreased by 15% and 39%, respectively, compared to 2019 [138] - AGC does not manufacture or use PFAS substances listed as Persistent Organic Pollutants under the Stockholm Convention [148]